Shareholders back IDEAYA (NASDAQ: IDYA) proposals as board names new chair
Rhea-AI Filing Summary
IDEAYA Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026. As of the April 20, 2026 record date, 87,860,920 common shares were outstanding and entitled to vote.
Stockholders voted on three proposals. For director elections, Yujiro S. Hata received 70,546,418 votes for and 2,470,077 withheld, M. Garret Hampton received 56,718,637 for and 16,297,858 withheld, and Catherine J. Mackey received 70,281,521 for and 2,734,974 withheld, with 10,089,343 broker non-votes for each nominee.
PricewaterhouseCoopers LLP, as independent registered public accounting firm for the year ending December 31, 2026, received 82,579,758 votes for, 141,240 against, and 384,840 abstentions. The non-binding advisory vote on executive compensation received 64,269,756 votes for, 8,349,131 against, 397,608 abstentions, and 10,089,343 broker non-votes.
Effective June 16, 2026, the Board elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as Lead Independent Director.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.07, 8.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Shares entitled to vote: 87,860,920 shares
Votes for Yujiro S. Hata: 70,546,418 votes
Votes for Catherine J. Mackey: 70,281,521 votes
+3 more
6 metrics
Shares entitled to vote
87,860,920 shares
Common stock outstanding as of April 20, 2026 record date
Votes for Yujiro S. Hata
70,546,418 votes
Director election at 2026 Annual Meeting
Votes for Catherine J. Mackey
70,281,521 votes
Director election at 2026 Annual Meeting
Votes for M. Garret Hampton
56,718,637 votes
Director election at 2026 Annual Meeting
Auditor ratification support
82,579,758 votes for
Ratification of PricewaterhouseCoopers LLP for year ending December 31, 2026
Say-on-pay support
64,269,756 votes for
Non-binding advisory vote on executive compensation
Key Terms
broker non-votes, non-binding, advisory vote, independent registered public accounting firm, Lead Independent Director, +1 more
5 terms
broker non-votes financial
"Broker Non-Votes 64,269,756 | | 8,349,131 | | 397,608 | | 10,089,343"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding, advisory vote regulatory
"The non-binding, advisory vote to approve the compensation of the Company’s named executive officers"
independent registered public accounting firm financial
"PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Lead Independent Director financial
"elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as the Board’s Lead Independent Director"
A lead independent director is a board member who is not part of company management and is chosen to coordinate and represent the other independent directors, often running sessions without the CEO, helping set meeting agendas, and serving as a liaison between shareholders and the board. For investors, this role signals stronger, more balanced oversight—like a neutral referee who helps ensure decisions are fair, transparent and focused on protecting shareholder interests.
Annual Meeting of Stockholders regulatory
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)"
FAQ
What did IDEAYA Biosciences (IDYA) report from its 2026 annual meeting?
IDEAYA Biosciences reported voting results from its 2026 Annual Meeting of Stockholders. Shareholders voted on director elections, ratification of PricewaterhouseCoopers LLP as auditor, and a non-binding advisory vote on executive compensation, with detailed vote counts disclosed for each proposal.
Which directors were up for election at IDEAYA Biosciences’ 2026 meeting?
Three Class I directors stood for election to serve until the 2029 annual meeting. Nominees were Yujiro S. Hata, M. Garret Hampton, Ph.D., and Catherine J. Mackey, Ph.D., each receiving tens of millions of votes for, plus broker non-votes reported separately.
What were the results of IDEAYA Biosciences’ say-on-pay vote in 2026?
In the non-binding advisory vote on named executive officer compensation, IDEAYA Biosciences shareholders cast 64,269,756 votes for, 8,349,131 votes against, and 397,608 abstentions. There were 10,089,343 broker non-votes reported for this proposal under applicable stock exchange rules.
What leadership changes did IDEAYA Biosciences’ board make on June 16, 2026?
Effective June 16, 2026, the Board of Directors elected Yujiro S. Hata as Chairman of the Board and appointed Terry Rosen, Ph.D., as Lead Independent Director. These roles are in addition to existing board responsibilities disclosed for each individual.
AI-generated analysis. How Rhea-AI works. Not financial advice.
